The first patients have been enrolled in the expanded indication trial for the CoreValve Evolut R next-generation, recapturable, self-expanding transcatheter aortic valve replacement (TAVR) system from Medtronic.
Toshiba will showcase its Aquilion ONE family of computed tomography (CT) systems at this year’s American College of Cardiology (ACC) annual meeting in Chicago, USA, April 2-4, 2016.
ReCor Medical has been granted US Food and Drug Administration investigational device exemption approval for the RADIANCE-HTN clinical trial. This trial will measure the effect of ReCor’s Paradise renal denervation system on blood pressure, in patients with hypertension.
REVA has reached its targeted patient enrolment of 110 for Cohort B of the FANTOM II clinical trial. This brings the total enrolment to 227 patients.
The first clinical use of BioVentrix’s closed-chest Revivent-TC transcatherter ventricular enhancement system in the UK has taken place at Freeman Hospital, Newcastle-upon-Tyne.
Interventional cardiologists at Northwestern Memorial Hospital, Chicago, USA have become the first in the mid-west of the USA, and the second nationally, to perform a minimally invasive tricuspid valve procedure using the Mitralign Trialign system.
Thirty-day results of Cardiovascular System’s Coronary Orbital Atherectomy System Study (COAST) have been reported at a late-breaking presentation at the 2016 Cardiovascular Research Technologies Conference (CRT) in Washington, USA.
The Mitralign percutaneous annuloplasty system (MPAS) has received CE mark approval from the British Standards Institution for the treatment of functional mitral regurgitation (FMR). The product can now be marketed within the European Union.
The use of a stent to repair pulmonary artery stenosis in children and adults with congenital heart disease was successful in the majority of patients, but many also experienced serious complications, according to a study published today in the Journal of the American College of Cardiology.
Pil Hyung Lee (Department of Cardiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea) and others report that successful percutaneous coronary intervention (PCI) of a native chronic total occlusion lesion is not associated with improved long-term survival compared with a failed procedure. However, successful procedures are associated with significantly less target vessel revascularisation and coronary artery bypass grafting (CABG).
Magnesium Elektron and Biotronik have partnered to develop the SynerMag bioresorbable magnesium alloys for applications in cardiovascular medicine.
Palmaz Scientific has filed for chapter 11 bankruptcy protection in San Antonio. According to a company release, this action has been taken to provide adequate time to identify and evaluate prospective buyers for its metallurgical medical device technology.
Corvia Medical has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) for a multicentre clinical study of the company’s InterAtrial shunt device (IASD) for the treatment of heart failure. The company also announced that it has entered into an exclusive option-to-purchase agreement with an undisclosed strategic partner.
Women are less likely to receive basic life support for cardiac arrest from members of the public then men according to a study, the European Society of Cardiology announced on the 2016 International Women’s Day (8 March).
The US Food and Drug Administration (FDA) has approved the Sapien XT transcatheter heart valve (Edwards Lifesciences) for an expanded indication relating to pulmonic valve replacement procedures.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos